Anti-TRIP12 Antibody

Homeostasis, Stem Cells

Boster Bio Anti-TRIP12 Antibody (Catalog # A05449). Tested in ELISA, WB, IHC-P, IF, ICC applications. This antibody reacts with Human, Mouse, Rat.

TRIP12

1 mg/mL

Bovine

TRIP12 antibody was raised against a 18 amino acid peptide near the carboxy terminus of human TRIP12. The immunogen is located within amino acids 1930 - 1980 of TRIP12.

TRIP12 antibody is affinity chromatography purified via peptide column.

Thyroid hormone receptor interactor 12

E3 ubiquitin-protein ligase involved in ubiquitin fusion
degradation (UFD) pathway and regulation of DNA repair. Part of
the ubiquitin fusion degradation (UFD) pathway, a process that
mediates ubiquitination of protein at their N-terminus, regardless
of the presence of lysine residues in target proteins. In normal
cells, mediates ubiquitination and degradation of isoform
p19ARF/ARF of CDKN2A, a lysine-less tumor suppressor required for
p53/TP53 activation under oncogenic stress. In cancer cells,
however, isoform p19ARF/ARF and TRIP12 are located in different
cell compartments, preventing isoform p19ARF/ARF ubiquitination
and degradation. Does not mediate ubiquitination of isoform p16-
INK4a of CDKN2A. Also catalyzes ubiquitination of NAE1 and
SMARCE1, leading to their degradation. Ubiquitination and
degradation of target proteins is regulated by interaction with
proteins such as MYC, TRADD or SMARCC1, which disrupt the
interaction between TRIP12 and target proteins. Acts as a key
regulator of DNA damage response by acting as a suppressor of
RNF168, an E3 ubiquitin-protein ligase that promotes accumulation
of 'Lys-63'-linked histone H2A and H2AX at DNA damage sites,
thereby acting as a guard against excessive spreading of
ubiquitinated chromatin at damaged chromosomes.

Thyroid hormone receptor interactor 12